Masimo Corporation (MASI) recently announced that U.S.-based Yale-New Haven Hospital has upgraded its system to Masimo SET pulse oximetry, joining a growing global roster of health organizations using Masimo’s SET technology.
Masimo's SET pulse oximetry technology lessens measurement errors found in other types of pulse oximeters, and offers greater accuracy during patient low perfusion, an important consideration when patients are under anesthesia.
Masimo SET Measure-through Motion and Low Perfusion pulse oximetry is clinically shown to virtually eliminate false alarms and help clinicians detect life-threatening events.
In an effort to provide excellent care and deliver the best possible results for its patients, Yale-New Haven Hospital has standardized to Masimo’s SET pulse oximetry, both in the operating room and in the intensive care environment.
Pulse Oximetry
Pulse oximetry is a non-invasive method of monitoring a patient's oxygen saturation. Conventional pulse oximetry assumes that arterial blood is the only blood moving (pulsating) in the measurement site. However, during patient motion, the venous blood is also in motion, which can cause conventional pulse oximetry to under-read arterial oxygen saturation levels because it cannot distinguish between arterial and venous blood.
Masimo Signal Extraction Technology (SET) identifies venous blood signal (which has a lower oxygen saturation level than arterial blood), isolates it, and uses adaptive filters to report accurate arterial oxygen saturation and pulse rate.
Clinical Evidence
Masimo SET technology has been clinically proven in over 100 independent studies to be the most accurate pulse oximetry under the most challenging conditions of motion and low perfusion. These studies have shown significant improvements in false alarm rejection, true alarm detection, drop outs (failure to operate), and accuracy.
Additional studies have also shown the impact of Masimo SET on patient outcomes and cost of care. It helps clinicians detect congenital heart disease in newborns, reduce ventilator weaning time and arterial blood gas measurements in the ICU through more reliable SpO2 measurements, and decrease rapid response activations and ICU transfers through earlier identification of patients in distress.
Masimo SET pulse oximetry also helps reduce retinopathy of prematurity (ROP) in premature infants, an eye disorder that can lead to blindness. A recently published study in the Journal of Perinatology showed that after the neonatal intensive care unit at Yale-New Haven Children's Hospital switched to Masimo SET pulse oximetry, there was a 37% lower rate of severe ROP and a 53% reduction in ROP requiring surgery rate.
Zacks Rank
Currently, Masimo carries a Zacks Rank #3 (Hold). Some better-ranked medical instrument stocks include Alphatec Holdings, Inc. (ATEC), ERBA Diagnostics, Inc. (ERB) and RTI Surgical Inc. (RTIX). All these stocks sport a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
To read this article on Zacks.com click here.
Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.
Be the first to comment